Japanese (NIKKEI) Pharma Industry Analysis

Industry Valuation and Performance

Has the Japanese Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 25 Jun 2026	JP¥43.8t	JP¥17.5t	JP¥1.9t	16.2x	23.5x	2.5x
Sat, 23 May 2026	JP¥45.9t	JP¥17.5t	JP¥2.2t	16.7x	20.8x	2.6x
Mon, 20 Apr 2026	JP¥48.8t	JP¥17.3t	JP¥2.2t	15.3x	22.4x	2.8x
Wed, 18 Mar 2026	JP¥50.8t	JP¥17.3t	JP¥2.2t	16.1x	23.3x	2.9x
Fri, 13 Feb 2026	JP¥50.2t	JP¥17.2t	JP¥2.3t	15.4x	22.2x	2.9x
Sun, 11 Jan 2026	JP¥47.9t	JP¥16.9t	JP¥1.9t	16.6x	25.2x	2.8x
Tue, 09 Dec 2025	JP¥45.3t	JP¥16.9t	JP¥1.9t	15.3x	23.8x	2.7x
Thu, 06 Nov 2025	JP¥40.9t	JP¥16.9t	JP¥1.9t	13.9x	21.2x	2.4x
Sat, 04 Oct 2025	JP¥41.2t	JP¥16.8t	JP¥1.8t	15.6x	22.6x	2.5x
Mon, 01 Sep 2025	JP¥40.2t	JP¥16.8t	JP¥1.8t	15.5x	22x	2.4x
Wed, 30 Jul 2025	JP¥41.0t	JP¥16.8t	JP¥1.7t	17.1x	23.5x	2.4x
Fri, 27 Jun 2025	JP¥40.3t	JP¥16.8t	JP¥1.8t	15x	22.8x	2.4x
Sun, 25 May 2025	JP¥40.1t	JP¥16.8t	JP¥1.8t	14.5x	22.8x	2.4x
Tue, 22 Apr 2025	JP¥40.3t	JP¥16.5t	JP¥1.5t	14.5x	26.7x	2.4x
Thu, 20 Mar 2025	JP¥40.4t	JP¥16.5t	JP¥1.5t	16.2x	26.9x	2.4x
Sat, 15 Feb 2025	JP¥40.1t	JP¥16.4t	JP¥1.3t	16.7x	30.7x	2.4x
Mon, 13 Jan 2025	JP¥40.8t	JP¥16.1t	JP¥1.4t	16x	28.9x	2.5x
Wed, 11 Dec 2024	JP¥42.3t	JP¥16.1t	JP¥1.4t	15x	29.9x	2.6x
Fri, 08 Nov 2024	JP¥44.8t	JP¥16.0t	JP¥1.4t	16.2x	32x	2.8x
Sun, 06 Oct 2024	JP¥44.2t	JP¥15.5t	JP¥1.2t	15.9x	36.8x	2.8x
Tue, 03 Sep 2024	JP¥47.3t	JP¥15.5t	JP¥1.2t	17.8x	39.3x	3x
Thu, 01 Aug 2024	JP¥46.4t	JP¥15.1t	JP¥1.1t	18.6x	41.7x	3.1x
Sat, 29 Jun 2024	JP¥42.4t	JP¥15.0t	JP¥1.1t	18.2x	38.7x	2.8x
Mon, 27 May 2024	JP¥40.3t	JP¥15.0t	JP¥1.1t	16.5x	36.8x	2.7x
Wed, 24 Apr 2024	JP¥39.6t	JP¥14.8t	JP¥1.2t	18.8x	32.8x	2.7x
Fri, 22 Mar 2024	JP¥43.6t	JP¥15.1t	JP¥1.2t	19.9x	35.9x	2.9x
Sun, 18 Feb 2024	JP¥42.5t	JP¥15.1t	JP¥1.2t	21.4x	35x	2.8x
Tue, 16 Jan 2024	JP¥42.6t	JP¥15.2t	JP¥1.4t	20.2x	30.9x	2.8x
Thu, 14 Dec 2023	JP¥39.5t	JP¥15.2t	JP¥1.4t	19.6x	28.8x	2.6x
Sat, 11 Nov 2023	JP¥38.7t	JP¥15.1t	JP¥1.4t	22.7x	28.1x	2.6x
Mon, 09 Oct 2023	JP¥39.1t	JP¥14.9t	JP¥1.4t	23.1x	27.4x	2.6x
Wed, 06 Sep 2023	JP¥40.7t	JP¥14.9t	JP¥1.4t	23.5x	28.5x	2.7x
Fri, 04 Aug 2023	JP¥38.9t	JP¥14.9t	JP¥1.4t	21.1x	27.1x	2.6x
Sun, 02 Jul 2023	JP¥40.0t	JP¥14.6t	JP¥1.5t	20.8x	27.4x	2.7x

Current Industry PE

Investors are pessimistic on the Japanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 23.5x which is lower than its 3-year average PE of 28.2x.

The industry is trading close to its 3-year average PS ratio of 2.7x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have grown 8.4% per year over the last three years.
Revenues for these companies have grown 6.1% per year.
This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Japanese Healthcare industry?


JP Market	-1.29%
Healthcare	-0.39%
Pharma	0.59%
Pharma	0.59%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
4536 Santen Pharmaceutical	JP¥2.13k	12.7% +JP¥77.0b	28.2%	PE18.3x
4528 Ono Pharmaceutical	JP¥2.34k	2.8% +JP¥29.8b	52.5%	PE15.8x
4151 Kyowa Kirin	JP¥2.56k	2.2% +JP¥28.5b	3.4%	PE18.4x
4502 Takeda Pharmaceutical	JP¥5.05k	0.3% +JP¥26.9b	16.0%	PS1.8x
4553 Towa Pharmaceutical	JP¥3.84k	4.5% +JP¥8.1b	28.0%	PE36x

Takeda Pharmaceutical Company Limited Announces Management and Committee Changes

Takeda Pharmaceutical Company Limited announced new appointments and assignments of directors and committee members following the 150th Annual General Meeting of Shareholders held in Osaka, Japan. Shareholders elected members of the Board of Directors, including three new external directors: Bruce Broussard, Koichiro Kimura and Dr. Paul Stoffels. Mr. Broussard brings decades of leadership experience with large global companies and international business management, and deep expertise in the U.S. healthcare system. As the former Chairman of PricewaterhouseCoopers in Japan, Mr. Kimura has extensive experience in geopolitical risk and corporate governance across the Asia-Pacific region. Dr. Stoffels brings an exceptional track record in pharmaceutical R&D innovation, having overseen the global launch of 25 medicines, first as Chief Science Officer at Johnson & Johnson, and then as CEO of biotechnology company Galapagos. At the Board of Directors and the Audit and Supervisory Committee meetings following the Annual Meeting of Shareholders, new assignments of directors were determined. Takeda's Board of Directors has eight members serving as external directors out of a total of 11 members. An external director will continue to chair the Board of Directors meeting. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. New assignments of directors who are not Audit and Supervisory Committee members (effective June 24, 2026): Julie Kim (Representative Director, President & Chief Executive Officer), Milano Furuta (Director, Chief Financial Officer), Andrew Plump (Director, President, Research & Development), Masami Iijima (External Director, Chair of the Board Meeting), Steven Gillis (External Director), John Maragnore (External Director), Paul Stoffels (External Director), Miki Tsusaka (External Director). Dr. Paul Stoffels is also a Substitute Audit and Supervisory Committee member. Directors who are Audit and Supervisory Committee members (effective June 24, 2026): Koichiro Kimura (External Director, Head of Audit and Supervisory Committee), Bruce Broussard (External Director, Audit and Supervisory Committee Member), Kimberly A. Reed (External Director, Audit and Supervisory Committee Member). New assignment of Nomination Committee members (effective June 24, 2026): Masami Iijima (Chairperson), Steven Gillis and Koichiro Kimura (Observer: Julie Kim). New assignment of Compensation Committee members (effective June 24, 2026): John Maraganore (Chairperson), Masami Iijima, Kimberly A. Reed, Miki Tsusaka. Upon conclusion of the meeting, Christophe Weber retired from the Company and the Board. In the final step of its 18-month CEO transition, company announced Julie Kim was officially appointed Takeda's Representative Director and President. Upon conclusion of the meeting, former president & CEO Christophe Weber retired from the Company and the Board. The following is biography of Julie Kim. Date of Birth is June 6, 1970. Business Experience includes: Joined Shire plc in June 2016, In June 2016 was Head of International Value Demonstration & Access. In May 2018 was Head of Global Hematology Franchise. In January 2019 Joined Takeda Pharmaceutical Company Limited. In January 2019 was President, Plasma-Derived Therapies Business Unit. In April 2022 was President, U.S. Business Unit, and U.S. Country Head. In August 2025 was President, U.S. Business Unit, U.S. Country Head and Interim Head, Global Portfolio Division. In September 2025, Director and Chief Executive Officer, Takeda Pharmaceuticals U.S.A. Inc. (present). In November 2025 was Interim Head, Global Portfolio Division. In January 2026 was CEO-Elect. In June 2026 is Representative Director, President & CEO (present).

Japanese (NIKKEI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Daiichi Sankyo Company, Limited to Report Q1, 2027 Results on Jul 31, 2026

Takeda Pharmaceutical Company Limited Announces Management and Committee Changes

Towa Pharmaceutical Co., Ltd. Announces Director Appointments

New major risk - Revenue and earnings growth

4503: KRAS Oncology And AI Overhaul Will Likely Strain Future Returns

Upcoming dividend of JP¥66.00 per share

Upcoming dividend of JP¥70.00 per share

Upcoming dividend of JP¥35.00 per share

Price target increased by 7.3% to JP¥2,458

Shionogi & Co., Ltd. Achieves Primary Endpoint in Global Phase 3 Clinical Trial of Orolofim

Eisai (TSE:4523) Stock Could Be 21.8% Undervalued After UK Investment Backing

Sumitomo Pharma Completes Enrollment for Key Phase 2 Enzomenib Leukemia Study

Price target increased by 26% to JP¥2,700

Nxera’s Vamorolone Granted Global Innovative Products on Fast Track Designation Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Santen Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 06, 2026

KYORIN Pharmaceutical's (TSE:4569) Anemic Earnings Might Be Worse Than You Think